
Business and Finance
Latest News

In today’s Pharma Pulse, federal officials slash the childhood immunization schedule, new data underscores the life-saving impact of COVID vaccines for COPD patients, and Eli Lilly targets the AMPK pathway in a massive new oral obesity collaboration.
Latest Videos

Podcasts
More News

In the first part of her Pharma Commerce video interview, Tina Martinez, vice president and head of global products and solutions at Cencora, describes how the company uses deep customer relationships and cross-enterprise collaboration to develop new products and solutions that address evolving market dynamics, improve efficiency, and support healthier outcomes.

The acquisition strengthens Yusen Logistics’ healthcare footprint across Europe, adding specialized transportation, warehousing, digital, and GDP-compliant capabilities to its regional and global network.

The South Korea–based CDMO acquires its first US manufacturing facility in Rockville, MD, expanding its global footprint and strengthening biologics capacity.

Bill Roth, general manager and managing partner of IntegriChain’s consulting business, previews his new six-part series by outlining how rising payer fragmentation, divergent cash and insurance models, and supply-chain constraints are reshaping brand strategy.

The acquisition strengthens CEVA’s global project logistics footprint, adding heavy-lift expertise, specialized engineering talent, and integrated solutions across key regions.

The pharmaceutical giant’s new 700,000-square-foot hub aims to onshore production of key medicines and strengthen the US drug supply chain.

A session explores how manufacturers can refine GTN strategy, strengthen pricing governance, and navigate increasingly complex distribution-channel economics, while maintaining both commercial performance and patient affordability.

BioCare's Ryan Cort outlines the pharmaceutical industry's "unprecedented sea change," driven by over $400 billion in anticipated revenue loss from generics and biosimilars losing exclusivity.

Commercialization expert Bill Roth outlines the critical need for "adaptive capacity," detailing how accelerating government regulation and massive patent cliffs are forcing a complete overhaul of commercial strategies across various markets.

The entrepreneur urges the Trump administration to eliminate costly FDA generic drug fees, part of a broader push to scale domestic production, address shortages, and challenge PBM-driven pricing models.

The agreement includes exemptions for UK-produced drugs and medical devices from Section 232 tariffs, but mandates a significant change to the UK's NICE value appraisal framework.

The Trump administration has announced new negotiated Medicare prices for a second wave of blockbuster treatments, yielding an estimated $12 billion in savings for 2027, when compared to Medicare’s 2024 net spending.

As the federal government prepares to release newly negotiated Medicare drug prices, weight-loss blockbusters Ozempic and Wegovy remain in the spotlight, while CMS advances a model to cut Medicaid spending and broaden access to affordable treatments.

Moderna secures a $1.5 billion loan to enhance financial flexibility while targeting a 10% revenue growth by 2026, focusing on innovative mRNA therapies.

While studies reveal the complex, varying, and long-lasting burden of Long COVID symptoms, biopharma giants Novartis and Moderna commit significant capital to new facilities, reinforcing US drug supply resilience in today’s Pharma Pulse.














